This is the question that stops most women from considering hormone therapy, and it is almost always discussed without numbers — which is precisely what makes it frightening. Here is what the research actually shows, expressed as absolute risk rather than percentages designed to alarm, and set beside risks nobody warns you about at all.

Where we stand: Menova is an independent publication. We sell no hormones, we take no payment from any manufacturer, and we are not your doctor. This is general education to help you have an informed conversation, not medical advice or a recommendation.

Why relative risk misleads

Almost every headline about HRT uses relative risk — "a 26% increase" — which sounds enormous and tells you nothing on its own, because it is a percentage of a number you were never given.

Absolute risk is the number that matters: how many additional women out of a defined group are affected. A doubling of a rare risk is still rare. A small increase in a common risk can matter more.

When you talk to a clinician, the useful question is: "Out of 1,000 women like me, how many more would be affected?"

What the evidence shows

The starting point everyone should know: breast cancer risk rises with age regardless of hormone therapy, and around one in eight women will develop breast cancer in her lifetime. Any HRT effect sits on top of a baseline that is already substantial and already rising.

Broadly, what the research indicates:

  • Estrogen-only therapy — for women who have had a hysterectomy — has not been found to increase breast cancer risk in the main randomized trial evidence, and in the Women's Health Initiative estrogen-only arm the observed risk was, if anything, slightly lower.
  • Combined estrogen-plus-progestogen therapy is associated with a small increase in breast cancer risk, which appears to grow with duration of use and to decline after stopping.
  • The size of the increase is typically described by menopause societies as fewer than one additional case per 1,000 women per year of use in the age groups studied — an increase generally characterized as rare or very rare in standard risk terminology.
  • The type of progestogen may matter, with some observational evidence suggesting micronized progesterone compares more favorably than older synthetic progestins — see progesterone in menopause. This is suggestive rather than settled.

The comparison nobody offers

This is the part that changes how the number feels. Several everyday factors carry breast cancer risk of a similar or larger magnitude than combined HRT, and none of them come with a warning conversation:

  • Drinking alcohol regularly — a well-established, dose-dependent risk relationship; see alcohol in midlife
  • Being physically inactive
  • Carrying excess body weight after menopause, which raises circulating estrogen independently
  • Never having children, or a first pregnancy after 30

Pointing this out is not an argument for taking HRT. It is an argument for proportion: a woman who is told nothing about her nightly glass of wine and everything about a patch is not being given a balanced picture with which to decide.

What raises or lowers the number for you

Your personal figure is not the population average. Things that shift it:

  • Family history, particularly a first-degree relative with breast cancer, and known BRCA1 or BRCA2 variants
  • Your own history of breast cancer or certain high-risk breast conditions — in which case systemic HRT is generally not used, and non-hormonal options are the route; see non-hormonal menopause options
  • Duration of use — the association strengthens with years on combined therapy
  • Whether you have a uterus, which determines whether you need a progestogen at all
  • Your age at starting, which matters for the overall risk-benefit balance; see how long you can stay on HRT

The other side of the ledger

A risk conversation that only counts risks is not a decision aid. The same evidence base shows hormone therapy is the most effective treatment for hot flashes and night sweats, reduces bone loss and fracture risk, and effectively treats the vaginal and urinary symptoms that otherwise worsen over time. For women with early or premature menopause, it is generally recommended until around the average age of natural menopause because the comparison is not "risk versus no risk" — it is versus the health consequences of years without estrogen.

There is also the quality-of-life side, which is not a soft consideration when someone has not slept properly in two years.

What the 2025 labelling change did and did not do

In late 2025 the FDA announced removal of the boxed warning from many menopausal hormone therapy products, reflecting long-standing arguments that the class labelling overstated risk — particularly for low-dose vaginal products. What that changed is how the risk is framed on the box. It did not change the underlying evidence about combined therapy and breast cancer. Our article on the 2025 FDA change covers it in detail.

How to have this conversation

Ask for your numbers, not the population's:

  • Given my history, what is my baseline risk, and how much would this regimen change it in absolute terms?
  • Does estrogen-only apply to me, or do I need a progestogen — and which one?
  • How does this compare with the risks of not treating my symptoms?
  • What screening schedule do you recommend if I start?
  • When would we reassess?

Whatever you decide, keep up with screening, know how your breasts normally look and feel, and report any new lump, skin dimpling, or nipple change promptly — that applies to every woman, on hormones or not.

The free printable visit prep sheet has space for family history and the questions above, and our guide to HRT risks and benefits covers clots, stroke, and cardiovascular risk, which belong in the same conversation.

The honest summary

For most healthy women under 60 starting within ten years of menopause, the increase in breast cancer risk from combined hormone therapy is small in absolute terms, appears to relate to duration, and declines after stopping. It is real, it should be disclosed, and it should be weighed against effective symptom relief and against risks of comparable size that go undiscussed.

That balance is genuinely individual. Anyone who tells you HRT is definitely safe, or definitely dangerous, is selling you a simpler story than the evidence supports.

The free 2-minute Menova self-check helps you arrive with your symptom picture organized so this conversation is about your situation rather than headlines — no account, not a diagnosis, and your answers never leave your device.

For where these numbers came from and why a generation was told to stop, see what the WHI actually found. If you have the numbers and still cannot weigh them, see when you can't decide about HRT. Also: menopause after breast cancer, HRT, mammograms and breast density, and BRCA and risk-reducing surgery.

This article is general education, not medical advice, and not a recommendation for or against hormone therapy. Risk estimates are population averages and cannot be applied directly to an individual. Decide with a licensed clinician who knows your full history.

Sources: The Menopause Society, National Cancer Institute — Breast Cancer Risk, NICE NG23 — Menopause, and ACOG.